What is Cumberland Pharmaceuticals ROE % Adjusted to Book Value?
Cumberland Pharmaceuticals's ROE % for the quarter that ended in Dec. 2024 was -31.98%. Cumberland Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2024 was 1.45.
Cumberland Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -22.06%.
Cumberland Pharmaceuticals ROE % Adjusted to Book Value Historical Data
The historical data trend for Cumberland Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cumberland Pharmaceuticals ROE % Adjusted to Book Value Chart
Competitive Comparison of Cumberland Pharmaceuticals's ROE % Adjusted to Book Value
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPIX has been successfully added to your 